中南医学科学杂志2016，Vol.44Issue(6)：630-636,7.DOI:10.15972/j.cnki.43-1509/r.2016.06.007
复方苦参注射液联合放化疗治疗鼻咽癌疗效及安全性的Meta分析
Meta Analysis of Effectiveness and Safety of Compound Kushen Injection Combined with Radiation Treatment and Chemotherapy Drugs in the Treatment of Esophageal Carcinoma
摘要
Abstract
Objective To systematically evaluate the efficacy and safety of Compound Kushen Injection combined with radiation treatment and chemotherapy drugs in the treatment of esophageal carcinoma and to provide evidence-based ad-vice for clinical treatment by using Meta-Analysis. Methods The Cochrane Library(Issue 6,2015),Medline,EMbase, CBM,CNKI,VIP,WanFang Data were retrieved to collect the randomized controlled trials(RCT)that compared Compound Kushen Injection combined with radiation treatment and chemotherapy drugs( test group) with only radiation treatment and chemotherapy drugs(control group)for esophageal carcinoma.After the data extraction and quality assessment,Meta-analysis was performed by using RevMan 5.3 software. Results 7 RCTs that included 328 patients were selected.Odds ratio(95%confidence interval [CI];P value) was 2.00(1.27,3.13;P<0.05)for remission rate,0.35(0.24,0.51;P<0.05)for gradeⅢ~Ⅳ oral mucositis rate,0.39(0.25,0.60;P<0.05) for gradeⅢ~Ⅳradiation dermatitis rate,0.41(0.28,0.58;P<0. 05) for grade Ⅲ~Ⅳleukocyte reduction rate,the outcome showed significant differences. Conclusions Compared with radi-ation treatment and chemotherapy drugs alone,compound Kushen Injection combined with radiation treatment and chemo-therapy drugs might have better efficacy and safety for esophageal carcinoma.Due to the poor quality of included studies,it still needs more large-sample and high-quality RCTs with longer follow-up time to verify.关键词
复方苦参注射液/鼻咽癌/meta分析/系统评价/随机对照试验Key words
Compound Kushen Injection/Esophageal Carcinoma/Meta-Analysis/Systematic review/Ran-domized controlled trial分类
医药卫生引用本文复制引用
杨青廷,熊文婧,旷满华,李国峰,刘也,周平坤,让蔚清..复方苦参注射液联合放化疗治疗鼻咽癌疗效及安全性的Meta分析[J].中南医学科学杂志,2016,44(6):630-636,7.基金项目
国家863项目(2012AA063501)；疾病控制评价中心重点实验室建设经费(NHSYS04)；公共卫生与预防医学湖南省重点学科建设经费 （2012AA063501）
